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Abstract 
Background: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism 
is implicated in synaptic excitation and neuronal integrity, and has previously been 
shown to moderate Aβ-related memory decline and hippocampal atrophy in preclinical 
sporadic Alzheimer’s disease (AD).  However, the effect of BDNF in autosomal dominant 
AD (ADAD) is unknown.  We aimed to determine the effect of BDNF Val66Met on 
cognitive function, hippocampal function, tau and Aβ in preclinical ADAD.  We explored 
effects of apolipoprotein E (APOE) ε4 on these relationships. 
Methods: The Dominantly Inherited Alzheimer Network (DIAN) conducted clinical, 
neuropsychological, genetic, biomarker and neuroimaging measures at baseline in 131 
mutation non-carriers (NC) and 143 preclinical ADAD mutation carriers (MC) on 
average 12 years prior to clinical symptom onset.  BDNF genotype data were obtained 
for MCs (95 Val66 homozygotes, 48 Met66 carriers). 
Findings: Among preclinical MCs, Met66 carriers had worse memory performance, 
lower hippocampal glucose metabolism and increased levels of CSF tau and 
phosphorylated tau (p-tau) than Val66 homozygotes.  Cortical Aβ and CSF Aβ42 levels 
were significantly different from NC’s but did not differ between preclinical MC Val66 
homozygotes and Met66 carriers. There was an effect of APOE on Aβ levels but not 
cognitive function, glucose metabolism or tau. 
Interpretation:  As in sporadic AD, the deleterious effects of Aβ on memory, 
hippocampal function, and tau in preclinical ADAD mutation carriers are greater in 
Met66 carriers.  To date, this is the only genetic factor found to moderate downstream 
effects of Aβ in ADAD. 
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Introduction 
Alzheimer’s disease (AD) begins with the aggregation of beta-amyloid (Aβ), the 
development and spread of hyperphosphorylated tau (Ballatore et al. , 2007, Ittner and 
Götz, 2011), and ultimately neuronal and synaptic loss.  This characteristic pathological 
process manifests initially as cognitive impairment which increases progressively so 
eventually classification of dementia is warranted (Hardy and Higgins, 1992, Ittner and 
Götz, 2011, Spires-Jones and Hyman, 2014).  Clinical pathological relationships in AD 
are still not understood completely, however recent in vitro (Hariri et al. , 2003, Lee et 
al. , 2012), post-mortem (Buchman et al. , 2016, Garzon and Fahnestock, 2007, Peng et al. 
, 2005) and animal (Caccamo et al. , 2010, Lee et al. , 2012, Rosa and Fahnestock, 2015) 
studies suggest neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) 
moderate neuronal and synaptic dysfunction and their behavioral expression in AD 
(Fahnestock, 2011, Lu et al. , 2013).  
Clinical studies of the role of BDNF in AD are limited by the absence of validated 
biomarkers for central nervous system (CNS) BDNF (Forlenza et al. , 2010, Kim et al. , 
2015).  However, the BDNF Val66Met (rs6265) polymorphism Met protein can result in 
reduced dendritic trafficking and synaptic localization of the protein and up to a 30% 
reduction in activity-dependent BDNF secretion (Chen et al. , 2006, Egan et al. , 2003).   
In healthy young adults, memory dependent hippocampal activity is reduced in Met66 
carriers (Hariri et al. , 2003).  In the preclinical and prodromal stages of sporadic AD, 
prospective studies show Met66 carriers to have increased rates of decline in episodic 
memory and hippocampal atrophy relative to Val66 homozygotes (Feng et al. , 2013, Lim 
et al. , 2014, Lim et al. , 2013, Lim et al. , 2014).  These same studies observe rates of 
cortical Aβ accumulation to be unaffected by the Met66 allele (Lim et al. , 2014, Lim et al. 
, 2013), suggesting that BDNF Met66 may accelerate neuronal dysfunction and memory 
decline by moderating pathological processes downstream of cortical Aβ accumulation, 
such as tau aggregation.  
While the processes that give rise to cortical Aβ accumulation are likely to differ 
between sporadic and autosomal dominant AD, the effects of Aβ on neurodegeneration 
and cognition are similar, albeit occurring at markedly younger ages in ADAD (mean age 
of onset is 45 years) (Bateman et al. , 2012, Jack and Holtzman, 2013, Ryman et al. , 
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2014).   Therefore the aim of this study was to investigate the effects of the BDNF Met66 
allele on episodic memory, hippocampal function, Aβ and tau in ADAD.  The first 
hypothesis was that in preclinical ADAD mutation carriers (MCs), impairment in 
episodic memory and hippocampal function would be greater in individuals who carry 
at least one copy of the BDNF Met66 allele compared to Val66 homozygotes.  The second 
hypothesis was that cortical Aβ levels would be unrelated to variation in BDNF 
Val66Met.  The third hypothesis was that CSF tau levels would be greater in BDNF Met66 
carriers compared to Val66 homozygotes.  We also explored the extent to which carriage 
of the BDNF Met66 allele was associated with domains of cognition beyond episodic 
memory, neuronal function in the precuneus and CSF biomarkers of Aβ1-42 and 
phosphorylated tau (p-tau181).  Finally, while the apolipoprotein E (APOE) ε4 allele does 
not increase severity of clinical presentation in ADAD (Ryman et al. , 2014), we 
observed previously additive effects of the BDNF Met66 and APOE ε4 alleles on Aβ 
related cognitive decline in preclinical sporadic AD (Lim et al. , 2014).  Therefore, we 
also explored the extent to which APOE acts independently, or with BDNF, to impact 
disease processes in ADAD. 
Method 
Participants 
Individuals at risk for carrying a mutation for ADAD (i.e., presenilin 1 [PSEN1], 
presenilin 2 [PSEN2], or amyloid precursor protein [APP] mutations) were enrolled in the 
Dominantly Inherited Alzheimer Network (DIAN) study.  Participants from families with 
known pathogenic ADAD mutations were recruited from 197 families at six sites in the 
United States, one in the United Kingdom and three in Australia (Morris et al. , 2012). 
The process of recruitment and enrollment has been described in detail previously 
(Bateman et al. , 2012, Morris et al. , 2012).  Baseline data from 274 participants (131 
NCs, 143 preclinical MCs) who were cognitively normal, as defined by a Clinical 
Dementia Rating of 0, and who had completed assessments of cognitive function, 
neuroimaging and cerebrospinal fluid (CSF) sampling were included.  APOE genotype 
was determined for all individuals as part of the DIAN study protocol.  Additionally, for 
MCs, only individuals whose BDNF Val66Met polymorphism was available were 
included. Table 1 shows the demographic characteristics of each participant group. 
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Clinical Assessment 
Without reference to participants’ performance on the neuropsychological test 
battery, a clinician assessed each participant for the presence and severity of clinical 
symptoms of dementia at baseline.  This was operationalized using the Clinical 
Dementia Rating (CDR) scale, for which a CDR total score of 0 indicates cognitive 
normality (Morris, 1983).  Participants also completed the Mini Mental State 
Examination (MMSE) and the Geriatric Depression Scale (GDS) at baseline. 
Neuropsychological Assessment 
All participants were assessed using the DIAN neuropsychological test battery, 
which includes the Wechsler Memory Scale–Revised Logical Memory (Story A only, 
immediate and delayed recall) and Digit Span; Category Fluency (animals, vegetables); 
Trail Making Test A and B; Digit Symbol from the Wechsler Adult Intelligence Scale–
Revised (WAIS–R); the Boston Naming Test (30 odd items), letter fluency for F, A, and S, 
and immediate and delayed recall of a single presentation of a 16-item word list 
(Storandt et al. , 2014). These tasks have been described previously, and were 
administered according to standard protocols by trained research assistants (Storandt 
et al. , 2014). The process of standardization and quality control of neuropsychological 
assessments across all DIAN sites have also been described previously (Storandt et al. , 
2014). 
Outcome measures for each neuropsychological test were standardized against 
the baseline mean and standard deviation for the NC group. Standardized scores were 
then averaged to form four cognitive domain-specific composite scores for episodic 
memory (Logical Memory delayed recall, word list learning delayed recall); executive 
function (Letter Fluency, Trail Making Test B); language (Category Fluency animals + 
vegetables, Boston Naming Test); attention (Digit Span Forwards, Digit Symbol); and 
global cognition (Logical Memory delayed recall, word list learning delayed recall, Digit 
Symbol, MMSE) (Donohue et al. , 2014). 
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Genotyping 
Genotyping for pathogenic mutations in the APP, PSEN1, and PSEN2 genes were 
performed on DNA extracted from peripheral blood samples using methods described 
previously (Talbot et al. , 1994).   Samples were also genotyped with the Infinium 
HumanExomeCore V1.0 Beadchip (Illumina, Inc). Genotyping was performed at The 
Genome Technology Access Center (GTAC; https://gtac.wustl.edu/) at Washington 
University. All samples and genotypes underwent stringent quality control (QC). 
Genotype data were cleaned by applying a minimum call rate for SNPs and individuals 
(98%). SNPs not in Hardy-Weinberg equilibrium (P< 1×10−6) were excluded. No SNPs 
were removed because low mAF. Gender identification was verified by analysis of X-
chromosome SNPs. We tested for unanticipated duplicates using pairwise genome-wide 
estimates of proportion identity-by-descent using PLINK v1.9.  Genotype data for the 
BDNF Val66Met (rs6265) polymorphism was extracted from using PLINK.  Clinicians 
were blinded to all genetic information and genetic polymorphisms were not used 
diagnostically. BDNF Val66Met genotyping was performed only in samples from 
individuals with a known ADAD mutation. 
Neuroimaging 
Images obtained through positron emission tomography (PET) with the use of 
fluorodeoxyglucose (FDG) and Pittsburgh compound B (PiB) (FDG-PET and PiB-PET, 
respectively) were co-registered with individual MRI images for region-of-interest 
(ROI) determination. 3 Tesla volumetric T1-weighted MRI scans from DIAN participants 
were acquired and processed through FreeSurfer (Martinos Center, Boston, MA) as 
previously described (Benzinger et al. , 2013).  Amyloid imaging was performed with a 
bolus injection of approximately 15 mCi of [11C] PiB. Dynamic imaging acquisition 
started either at injection for 70 minutes or 40 minutes post-injection for 30 minutes. 
For analysis, PiB-PET data between 40 to 70 minutes were used. For PiB-PET, total 
neocortical SUVR was used to determine levels of cortical Aβ deposition, using 
cerebellar grey matter as the reference region and applying partial volume correction 
using a regional point spread function as previously described (Su et al. , 2015). 
Metabolic imaging with [18F] FDG-PET was performed with a 3D dynamic 
acquisition began 40 minutes after a bolus injection of approximately 5 mCi of FDG and 
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lasted for 20 minutes.  In accordance with previous reports (Bateman et al. , 2012), the 
ROIs selected for this study were the hippocampus and the precuneus, with decreased 
FDG SUVR indicating decreased glucose metabolism and therefore reduced neuronal 
function in that area.  The reference region used was the cerebellar cortex. 
Biochemical Analysis 
Fasted CSF was collected in the morning via lumbar puncture. Samples were 
shipped on dry ice to the DIAN biomarker core laboratory.  CSF concentrations of Aβ42, 
total tau, and tau phosphorylated at threonine 181 (ptau181) were measured by 
immunoassay (INNOTEST β-Amyloid1-42, Innogenetics). All values had to meet quality-
control standards, including a coefficient of variation of 25% or less, kit “controls” 
within the expected range as defined by the manufacturer, and measurement 
consistency between plates of a common sample that was included in each run. 
Estimated year of onset 
The estimated year from expected symptom onset (EYO) was calculated as the 
age of the participant at the time of the baseline assessment minus the mean age at 
onset of all other individuals with the same mutation type (Ryman et al. , 2014). 
Data Analysis 
The study hypotheses that in ADAD, MC BDNF Met66 carriage would be 
associated with greater impairment in memory and hippocampal function, higher CSF 
tau but not cortical AB levels were tested by submitting the episodic memory 
composite, PiB-PET Aβ, CSF tau and glucose metabolism in the hippocampus (FDG-PET) 
to separate analyses of covariance (ANCOVA).   In each ANCOVA, EYO was added as a 
covariate, and Group (NC, MC Val66/Val66, MC Met66) as a fixed factor.  Within each 
ANCOVA, two planned comparisons were constructed with the first comparing MC Val66 
homozygotes and MC Met66 carriers and the second comparing MC Val66 homozygotes 
to the NC group.  Exploratory analyses were conducted only if a statistically significant 
difference between the MC Val66 homozygote and MC Met66 carrier groups was 
observed for at least one of the primary outcome measures.  With this criterion met, the 
ANCOVAs were repeated for the remaining cognitive composite scores, CSF Aβ42, CSF p-
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tau181, and FDG-PET in the precuneus.  The extent to which the presence of the APOE ε4 
allele influenced the effect of BDNF on cognitive function, Aβ burden, tau and neuronal 
function was determined by repeating these analyses with ε4 status (carrier vs. non-
carriers) entered into all statistical models.  Finally, to further understand the effect of 
BDNF Val66Met on cognitive and biomarker outcomes in ADAD, we expressed each 
cognitive and biomarker outcome variable as a function of EYO.  For the primary 
outcomes, statistical significance was classified as p<.05.  This was to balance the risk of 
false positive findings against the identification of important relationships because (a) 
this is an exploratory investigation in a relatively new area in which an important 
clinical issue has been identified, (b) as all four primary outcome measures are 
recognized as part of the AD pathological process, changes in these will be correlated 
and (c) effect sizes (Cohen’s d) were used to guide interpretation about the 
meaningfulness of statistical tests and comparisons with effect sizes <0.2 were classified 
as trivial and not interpreted regardless of statistical significance (Cohen, 1988).   
Results 
Demographic and clinical characteristics 
MCs were significantly younger than NCs, although the EYO between MC Val66 
homozygotes and MC Met66 carriers did not differ significantly.  NC and MC groups did 
not differ on any other demographic characteristic.  While the inclusion criteria 
required all individuals to have a CDR score of 0, the CDR sum of boxes score was 
significantly higher in MC Met66 carriers than in MC Val66 homozygotes and NCs (Table 
1).  Groups did not differ in MMSE total scores or levels of depressive symptoms. 
Effect of BDNF Val66Met on episodic memory, cortical Aβ, CSF tau and glucose 
metabolism in the hippocampus 
 Group means and standard deviations for raw scores on each of the primary 
outcome cognitive and biomarker measures for each group are summarized on Table 2.   
The outcomes of the primary analyses are summarized on Figure 1 for episodic memory 
and Figure 2 for the AD biomarkers.  Statistically significant group differences between 
MC Val66 homozygotes and MC Met66 carriers were observed for episodic memory 
(Figure 1), glucose metabolism in the hippocampus and CSF tau, but not cortical Aβ 
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(Figure 2). Effect sizes for these comparisons were, by convention, moderate-to-large in 
magnitude for episodic memory, glucose metabolism in the hippocampus and CSF tau 
levels, but were trivial for levels of cortical Aβ.  No statistically significant differences 
between NC and MC Val66 homozygotes were observed for any of the primary outcome 
measures, with all differences small in magnitude.   
Effect of BDNF Val66Met on cognition, CSF Aβ42, CSF p-tau181 and glucose 
metabolism in the precuneus  
For each exploratory cognitive and biomarker outcome measure, raw group 
means and standard deviations are summarized on Table 2.  Figure 1 and 2 also 
summarises the outcomes of the exploratory analyses for cognitive measures and AD 
biomarkers respectively.   Statistically significant group differences, of a moderate-to-
large magnitude, were observed between MC Val66 homozygotes and MC Met66 carriers 
for CSF p-tau181 levels (Figure 2, exploratory outcomes) but not for glucose metabolism 
in the precuneus or for the executive function, language, attention or global cognition 
composites (Figure 1, exploratory outcomes).  There were also no statistically 
significant differences between MC Val66 homozygotes and MC Met66 carriers on CSF 
Aβ42 levels, with these differences small in magnitude (Figure 2, exploratory outcomes). 
When compared to NCs, MC Val66 homozygotes showed no statistically 
significant impairment in any domain of cognitive function (Figure 1) and did not differ 
significantly in the extent of glucose metabolism in the hippocampus or the precuneus 
(Figure 2). Compared to NCs, both MC Val66 homozygotes and MC Met66 carriers showed 
elevated levels of CSF tau and p-tau181, and increased PiB-PET SUVR and decreased CSF 
Aβ42 levels (Table 2).   
Effect of APOE ε4 on cognitive function, neuronal dysfunction, Aβ and tau 
Re-analyses of the primary hypotheses with the addition of APOE status 
indicated no significant main effect of APOE status and no significant interaction 
between APOE and BDNF status on any measure of cognitive function (Table 3). 
Similarly, there was no significant main effect of APOE or interaction between APOE and 
BDNF for any outcome measure of glucose metabolism or tau (Table 3). However, there 
was a significant main effect of APOE for both PiB-PET SUVR and CSF Aβ42, although 
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there were no significant interactions between APOE and BDNF for either measure 
(Table 3).  Post-hoc analyses showed that when compared to MC ε4 non-carriers, MC ε4 
carriers had significantly increased PiB-PET SUVR (d [95%CI = 0.45 [0.05, 0.85], p = .03) 
and decreased CSF Aβ42 levels (d [95%CI = 0.76 [0.34, 1.17], p <.001). 
Effect of BDNF Val66Met on the relationship between EYO and markers of 
cognitive and neuronal function, Aβ and tau 
 There were no statistically significant relationships between level of cognitive 
function and EYO in NCs or in MC Val66 homozygotes. However, the relationship 
between EYO and episodic memory was statistically significant and moderate in 
magnitude for MC Met66 carriers (Figure 3A).  Similarly, there were no statistically 
significant relationships between glucose metabolism in the hippocampus and EYO in 
NCs or in MC Val66 homozygotes. However, the relationship between glucose 
metabolism in the hippocampus and EYO was moderate in magnitude and statistically 
significant for MC Met66 carriers (Figure 3B). 
There was no relationship between levels of cortical Aβ and EYO in NCs, but 
there was a significant moderate association between cortical Aβ levels and EYO in MCs 
irrespective of BDNF Val66Met polymorphism (Figure 3C).  Similarly, while there was 
no association between CSF tau and EYO in NCs, there was a significant moderate 
association between CSF tau and EYO in MCs, irrespective of BDNF Val66Met genotype 
(Figure 3D), with MC Met66 carriers showing systematically higher levels of CSF tau 
relative to their EYO than MC Val66 homozygotes (Figure 3D). 
Discussion 
The results show that the presence of one copy of the BDNF Met66 allele 
increased the severity of impairment in episodic memory and hippocampal function in 
preclinical ADAD.   This effect is clinically important as the magnitude of memory 
impairment related to MC Met66 carriers was approximately double that observed in MC 
Val66 homozygotes. These findings in the DIAN cohort are consistent with the greater 
memory decline and hippocampal volume loss observed in older adults with preclinical 
or prodromal sporadic AD from the AIBL and ADNI studies (Feng et al. , 2013, Lim et al. , 
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2014, Lim et al. , 2013).  The results confirm therefore, in an independent sample, that 
BDNF is important to the preclinical presentation of AD. 
The current data support the first hypothesis that in preclinical MCs, impairment 
in memory and hippocampal function would be greater in Met66 carriers compared to 
Val66 homozygotes.  Compared to MC Val66 homozygotes, MC Met66 carriers had worse 
episodic memory function (Figure 1).  In contrast, no memory impairment was 
observed in MC Val66 homozygotes compared to NCs.  Similarly, hippocampal function, 
determined by cerebral glucose metabolism, was also reduced in MC Met66 carriers 
compared to MC Val66 homozygotes.  However, MC Val66 homozygotes did not show 
lower glucose metabolism compared to NCs.  As increased oxidative stress has been 
previously observed in females (Keaney et al. , 2003), it is possible that the sex of 
participants may better account for the memory impairment in MC Met66 carriers. 
However, re-analysis of all primary outcome measures suggest that even when the sex 
of participants was considered, the effect of BDNF Val66Met on memory impairment, 
hippocampal function and tau remains (Table 4). Finally, MC Met66 carriers who were 
estimated to be nearer to their expected year of clinical symptom onset (EYO) showed 
increased memory impairment and lower glucose metabolism in the hippocampus 
(Figure 3).  In contrast, EYO was not associated with memory impairment or glucose 
metabolism in NCs or MC Val66 homozygotes.  
The second hypothesis that cortical Aβ and CSF Aβ42 levels would be unrelated to 
allelic variation in BDNF Val66Met was also supported. Preclinical MC Met66 carriers 
and Val66 homozygotes had equivalent levels of higher cortical Aβ and CSF Aβ42.  
Furthermore, these group differences were, by convention, small (i.e., d<0.2; Figure 2) 
in magnitude indicating that absence of statistically significant differences was not due 
to insufficient statistical power.  Compared to NCs, both Met66 carriers and Val66 
homozygotes showed increased levels of cortical Aβ deposition and decreased levels of 
CSF Aβ42.   Similarly, cortical Aβ burden was higher in preclinical MCs who were nearer 
to their EYO; although this relationship was not moderated by the BDNF Val66Met 
polymorphism (Figure 3C).  Increased cortical Aβ and lower CSF Aβ42 levels have been 
observed previously in preclinical ADAD (Bateman et al. , 2012, Ryman et al. , 2014).  
The absence of any effect of Met66 carriage on Aβ burden in preclinical ADAD is also 
consistent with observations that Met carriage was unrelated to rates of cortical Aβ 
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accumulation over 3 years in preclinical and prodromal sporadic AD (Feng et al. , 2013, 
Lim et al. , 2014, Lim et al. , 2013).  Together, these findings suggest that the effect of the 
BDNF Met66 allele is independent of the effect of Aβ on risk for, and progression of, AD. 
The results also support the third hypothesis that CSF levels of tau would be 
greater in MC Met66 carriers compared to MC Val66 homozygotes.  Levels of both CSF tau 
and p-tau181 were increased substantially in preclinical MC Met66 carriers compared to 
preclinical MC Val66 homozygotes (Figure 2).  Compared to NCs, preclinical MC Val66 
homozygotes also showed increased levels of CSF tau and p-tau181, although not to the 
same extent as MC Met66 carriers. Despite the overall increase in these biochemical 
markers, strong relationships between EYO and CSF tau were observed in both MC Val66 
homozygotes and MC Met66 carriers, and the magnitude of these relationships were 
equivalent (Figure 3D).  Thus, while the Met66 allele hastens memory dysfunction in 
preclinical ADAD, it does not necessarily affect the rate at which p-tau181 accumulates in 
CSF.  Instead, substantial differences in CSF p-tau181 levels between MC Met66 carriers 
and MC Val66 homozygotes (Figure 2) suggest that MC Val66 homozygotes may have an 
increased level of resilience to the neurotoxic effects of tau and Aβ. 
Finally, we explored the extent to which APOE acts independently or with BDNF 
to impact disease processes in ADAD.  There were no independent effects of APOE ε4, or 
combined effects of APOE and BDNF, on cognition, neuronal function or CSF tau (Table 
3).  However, compared to MC ε4 non-carriers, MC ε4 carriers showed increased cortical 
Aβ and decreased CSF Aβ42.   This indicates that in prelinical ADAD, the abnormal 
accumulation of cortical Aβ resulting from pathogenic mutations is increased further by 
the APOE ε4 allele, although this increased Aβ was not associated with any greater 
impairment in cognition or neuronal function.  Importantly, the increase in cortical Aβ 
in MC ε4 carriers was not affected by the BDNF Met allele.  Thus, allelic variation in 
BDNF and APOE may affect different AD processes with ε4 increasing cortical Aβ 
accumulation and BDNF Met66 moderating Aβ related impairment in cognition and 
neuronal function through its effects on tau.  
Neuronal and synaptic loss characteristic of both sporadic and autosomal 
dominant AD is due to the combined accumulation of Aβ plaques and tau aggregation 
(Ballatore et al. , 2007, Ittner and Götz, 2011, Spires-Jones and Hyman, 2014).  
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Neuropathological and CSF biomarker studies show that in AD, cognitive impairment 
and synaptic loss are associated more strongly with the presence and number of 
neurofibrillary tangles than Aβ plaques (Bennett et al. , 2004, Giannakopoulos et al. , 
2003, Ingelsson et al. , 2004).  However, neuroimaging studies in preclinical AD report 
that higher cortical Aβ load is associated with greater rates of cognitive decline and 
progression to MCI (Lim et al. , 2014, Rowe et al. , 2013), with these effects mediated by 
the effect of Aβ on neurodegeneration (Jack and Holtzman, 2013, Lim et al. , 2015). In 
this context, dissociation of the effects of BDNF on Aβ and tau associated cognitive 
impairment observed here are important because they provide evidence that BDNF 
Met66 influences disease progression through effects on neuronal dysfunction and 
cognitive impairment associated with tau. 
The current observation that BDNF Met66 in preclinical ADAD was associated 
with increased tau, hippocampal dysfunction and memory impairment is consistent 
with the role that CNS BDNF plays in synaptic excitation, long-term potentiation and 
neuronal plasticity (Fahnestock, 2011, Forlenza et al. , 2010, Garzon and Fahnestock, 
2007, Hariri et al. , 2003, Lee et al. , 2012, Lu et al. , 2013, Peng et al. , 2005).  Evidence of 
a mechanistic relationship between BDNF and tau has been shown in cellular studies 
which demonstrate that BDNF can induce rapid dephosphorylation of tau through TrkB 
activation (Elliott et al. , 2005) and that BDNF loss in AD is specific to tangle-bearing 
neurons (Ferrer et al. , 1999).  This has prompted the hypothesis that there may be a 
direct relationship between CNS BDNF levels and tau (Belrose et al. , 2013), although 
this remains under investigation.  Even in the absence of a direct mechanistic link, the 
large and clinically important effects of BDNF Met66 on memory, hippocampal function 
and tau, observed in the current ADAD sample, indicate that studying allelic variation in 
BDNF Val66Met may help clarify pathological models of AD and may even provide a 
reference for the investigation of the effects and clinical consequences of other 
neurotrophic factors in AD. 
As we have noted (Lim et al. , 2013), genome-wide association studies (GWAS) of 
AD do not identify the BDNF Val66Met polymorphism as increasing the risk for AD 
(Lambert et al. , 2013).  One possible explanation for this is that GWAS typically use a 
clinical classification of dementia as the target phenotype.  Consequently, they may 
overlook the contribution of BDNF because the effects of this gene manifest only in the 
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earliest stages of the disease (Feng et al. , 2013, Lim et al. , 2014, Lim et al. , 2013).  This 
hypothesis is supported by GWAS of cognitive aging in non-demented older adults, 
where BDNF Val66Met has been associated with memory impairment and decline 
(Harris and Deary, 2011, Papenberg et al. , 2015).  Thus, the hypothesis arising from the 
current and previous studies (Lim et al. , 2014, Lim et al. , 2013, Lim et al. , 2014) is that 
in studies of cognitive aging, memory decline associated with BDNF Met66 may reflect 
occult AD as opposed to the effects of normal aging.  In contrast to BDNF, GWAS of AD 
identify carriage of APOE ε4 as increasing risk for AD (Lambert et al. , 2013).  We have 
also reported that in preclinical sporadic AD, the APOE ε4 allele increases the rate of 
memory decline and brain volume loss associated with high Aβ (Dore et al. , 2013, Lim 
et al. , 2014, Lim et al. , 2015).  We have also observed that Aβ+ older adults who carry 
both the APOE ε4 and BDNF Met66 allele show greater memory decline than those who 
carry either one by itself (Lim et al. , 2014).  Re-analysis of the current data taking into 
account APOE ε4 did not indicate any effect of APOE or any interaction between APOE 
and BDNF on cognition (Table 3).  The absence of any effect of APOE on cognition in this 
study is consistent with the results of a detailed meta-analysis of three ADAD cohorts 
which showed that APOE did not moderate age of clinical symptom onset (Ryman et al. , 
2014).  However, despite having no effect on cognitive function or clinical symptom 
onset, APOE ε4 was associated with increasing cortical Aβ levels in preclinical MCs.  
Consequently, one hypothesis for the absence of any APOE effect on cognitive and 
clinical outcomes in ADAD is that these outcomes are related more strongly to neuronal 
dysfunction and tau than to Aβ accumulation.  
This study demonstrates that the deleterious effects of Aβ in ADAD were 
increased in preclinical individuals who carried the BDNF Met66 allele.  Therefore, the 
results of this study also confirm the similarity between the development of dementia in 
ADAD and sporadic AD.  However, as the current findings are based on cross-sectional 
data, it will be necessary to replicate these results prospectively.  Nonetheless, the 
strength and consistency of our results with that in sporadic AD is important because 
they suggest that strategies designed to increase CNS BDNF levels may be a viable 
therapeutic alternative or addition to those which seek to reduce the neurotoxic effects 
of Aβ.  Our results also suggest strongly that the BDNF Val66Met polymorphism should 
be considered as a potential moderator of clinical trial outcomes in current treatment 
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and prevention trials in ADAD and sporadic AD (Donohue et al. , 2014, Mills et al. , 
2013).   
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Table 1. Demographic and clinical characteristics 
 NC 
(n=131) 
MC Val66/Val66 
(n=95) 
MC Met66 
(n=48) 
p 
N (%) Female 58 (44.3%) 37 (38.9%) 25 (52.1%) .325 
N (%) APOE ε4 carrier 39 (29.8%) 24 (25.3%) 12 (25.0%) .784 
Age 38.37 (10.13) 34.45 (8.54) 35.12 (9.51) .012 
Est. Year of Onset N/A -12.44 (8.11) -12.70 (7.60) .855 
Years of Education 14.79 (2.64) 14.72 (3.54) 14.24 (2.56) .328 
GDS 1.24 (1.66) 1.45 (1.83) 1.47 (1.60) .566 
CDR sum of boxes 0.01 (0.06) 0.02 (0.10) 0.06 (0.17) .005 
MMSE 29.20 (1.17) 28.97 (1.37) 29.04 (0.99) .340 
Note: NC = Mutation non-carrier; MC = mutation carrier; GDS = Geriatric Depression 
Scale; HADS = Hospital Anxiety and Depression Scale; MACQ = Memory Complaints 
Questionnaire; CDR = Clinical Dementia Rating scale; MMSE = Mini-Mental State 
Examination 
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Table 2. Differences in each cognitive marker and biomarker between mutation non-carriers, mutation carriers who are BDNF Val66 
homozygotes, and mutation carriers who are BDNF Met66 carriers. 
 EYO Group NC  MC Val66/Val66  MC Met66  
Primary Outcomes (df) F p (df) F p Mean (SD) N Mean (SD) N Mean (SD) N 
Episodic Memory  (1,268) 20.87 .00 (2,268) 5.35 .00 0.03 (0.82) 131 -0.12 (0.83) 95 -0.43 (0.83) 48 
PiB-PET SUVR (1,223) 18.31 .00 (2,223) 38.85 .00 1.04 (0.54) 106 1.62 (0.53) 82 1.74 (0.53) 39 
CSF tau (1,216) 16.20 .00 (2,216) 19.94 .00 57.18 (40.42) 101 82.83 (40.29) 80 102.15 (40.29) 39 
FDG-PET hippocampus (1,225) 12.13 .00 (2,225) 3.91 .02 1.25 (0.09) 109 1.26 (0.09) 80 1.21 (0.09) 40 
           
Exploratory Outcomes           
Executive Function  (1,268) 2.23 .14 (2,268) 2.10 .12 0.02 (0.80) 131 -0.15 (0.81) 95 -0.22 (0.81) 48 
Language  (1,267) 0.28 .60 (2,267) 2.90 .06 0.03 (0.86) 131 -0.15 (0.86) 95 -0.29 (0.86) 48 
Attention  (1,268) 2.20 .14 (2,268) 4.00 .02 0.01 (0.81) 131 -0.15 (0.81) 95 -0.37 (0.81) 48 
Global Cognition (1,267) 8.36 .00 (2,267) 3.58 .03 0.02 (0.65) 131 -0.12 (0.65) 95 -0.26 (0.66) 48 
CSF Aβ42 (1,213) 8.03 .01 (2,213) 7.55 .00 430.72 (147.29) 99 355.78 (146.91) 78 346.57 (146.79) 40 
CSF p-tau181 (1,217) 8.12 .01 (2,217) 32.22 .00 29.27 (22.75) 101 48.48 (22.69) 80 60.62 (22.67) 40 
FDG-PET precuneus (1,225) 4.62 .03 (2,225) 1.13 .33 2.79 (0.29) 109 2.74 (0.29) 80 2.73 (0.29) 40 
Note: EYO = estimated year of symptom onset; Group = effect of group membership as NC, MC Val66 homozygote or MC Met66 carrier; all models have been adjusted 
for estimated year of symptom onset; bolded values are significant at the p < .05 or p < .001 level 
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Table 3. Effect of estimated year of symptom onset (EYO), APOE ε4 status, BDNF Val66Met status, and the interaction between APOE and 
BDNF on each cognitive and biomarker outcome measure 
 EYO APOE Group BDNF Group APOE  x BDNF Group 
Primary Outcomes (df) F p (df) F p (df) F p (df) F p 
Episodic Memory (1,266) 19.32 .00 (1,266) 1.79 .18 (1,266) 3.84 .05 (1,266) 0.08 .77 
PiB-PET SUVR (1,221) 16.73 .00 (1,221) 7.21 .01 (1,221) 2.65 .11 (1,221) 1.18 .28 
CSF tau (1,214) 15.50 .00 (1,214) 0.24 .63 (1,214) 4.06 .04 (1,214) 0.05 .82 
FDG-PET hippocampus (1,223) 11.88 .00 (1,223) 0.05 .83 (1,223) 6.03 .02 (1,223) 0.09 .77 
         
Exploratory Outcomes         
Executive Function  (1,266) 2.50 .12 (1,266) 0.93 .34 (1,266) 0.08 .78 (1,266) 0.08 .78 
Language (1,266) 0.20 .65 (1,266) 0.39 .54 (1,266) 0.99 .32 (1,266) 0.15 .70 
Attention (1,266) 2.40 .12 (1,266) 1.46 .23 (1,266) 2.78 .10 (1,266) 0.49 .49 
DIAN Composite (1,266) 8.14 .01 (1,266) 0.04 .84 (1,266) 0.84 .36 (1,266) 0.06 .81 
CSF Aβ42 (1,211) 6.94 .01 (1,211) 9.28 .00 (1,211) 0.02 .90 (1,211) 1.39 .24 
CSF p-tau181 (1,215) 7.39 .01 (1,215) 2.00 .16 (1,215) 4.60 .03 (1,215) 0.34 .56 
FDG-PET precuneus (1,223) 4.82 .03 (1,223) 0.65 .42 (1,223) 0.001 .98 (1,223) 0.02 .91 
Note: all models have been adjusted for estimated year of symptom onset (EYO); APOE Group indicates effect of group membership as 
NC, APOE ε4 carrier or APOE ε4 non-carrier; BDNF Group indicates effect of group membership as NC, MC Val66 homozygote or MC Met66 
carrier; bolded values are significant at the p < .05 level 
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Table 4. Re-analysis of the effect of BDNF Val66Met on each primary outcome variable, covarying for the potential confounding effect of 
sex 
 EYO Sex BDNF Group 
 (df) F p (df) F p (df) F p 
Episodic Memory (1,267) 13.96 .00 (1,267) 8.24 .00 (2,267) 5.17 .00 
PiB-PET SUVR (1,222) 18.43 .00 (1,222) 0.01 .92 (2,222) 40.59 .00 
CSF tau (1,215) 17.02 .00 (1,215) 0.56 .46 (2,215) 20.98 .00 
FDG-PET hippocampus (1,224) 5.60 .02 (1,224) 1.35 .25 (2,224) 3.95 .02 
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Figure Captions 
Figure 1. Magnitude of cognitive impairment in preclinical MC Val66 homozygotes and 
preclinical MC Met66 carriers when compared to mutation non-carriers (error bars 
represent 95% confidence intervals) (statistical significance occurs when 95% 
confidence intervals do not cross “0” line). 
Figure 2. Magnitude of abnormality on markers of Aβ, tau and glucose metabolism in 
preclinical MC Val66 homozygotes and preclinical MC Met66 carriers when compared to 
mutation non-carriers (error bars represent 95% confidence intervals) (statistical 
significance occurs when 95% confidence intervals do not cross “0” line). 
Figure 3. Relationship between estimated year of clinical symptom onset and episodic 
memory performance (A), glucose metabolism in the hippocampus (B), cortical Aβ 
levels (C), and CSF p-tau181 levels (D), in mutation non-carriers, preclinical MC Val66 
homozygotes, and preclinical MC Met66 carriers.  
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